

Provided by:



## Cancer Genomics Conference 2025-2026 2025

### Cancer Genomics Conference The Molecular Landscape of Melanoma. 2025-2026 - 6/24/2025

June 24, 2025

8:00 AM - 9:00 AM

#### Target Audience

This program has been designed for DERMATOLOGY, CLINICAL GENETICS AND GENOMICS (MD), INTERNAL MEDICINE - Hematology, INTERVENTIONAL RADIOLOGY AND DIAGNOSTIC RADIOLOGY, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - CLINICAL, RADIATION ONCOLOGY, SURGERY, THORACIC AND CARDIAC SURGERY, PATHOLOGY-ANATOMIC/PATHOLOGY-CLINICAL

#### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss basic principles, applications, and pitfalls of genomic testing
- 2 Discuss how to identify external resources and tools to aid in interpretation of genomic data
- 3 Describe how to communicate effectively between relevant disciplines

#### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

#### Acknowledgement of Commercial Support\*

None

For more information, please contact  
Deven Ginyard  
(215) 662-6318  
dginyard@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Salvatore Priore, MD, PhD	Co-Director	Honoraria-Thermo Fisher Scientific (Relationship has ended)   Consulting Fee-MCG Health   Consulting Fee-Palmetto GBA (Relationship has ended)   Honoraria-Sectra (Relationship has ended) - 04/08/2025
Melina Marmarelis, MD	Co-Director	Consulting Fee-Novocure (Relationship has ended)   Honoraria-Bayer (Relationship has ended)   Consulting Fee-Astra Zeneca Pharmaceuticals   Consulting Fee-Janssen Pharmaceuticals (J&J)   Consulting Fee-Takeda Pharmaceuticals (Relationship has ended)   Consulting Fee-Bristol-Myers Squibb (Relationship has ended)   Grant or research support-Eli Lilly   Consulting Fee-Blueprint Pharmaceuticals (Relationship has ended)   Advisor-Ikena (Relationship has ended)   Grant or research support-Merck & Co   Grant or research support-Astra Zeneca Pharmaceuticals   Stocks or stock options, excluding diversified mutual funds-Gilead Sciences, Inc (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Merck & Co   Stocks or stock options, excluding diversified mutual funds-Novartis (Advanced Health Media) (Relationship has ended)   Stocks or stock options, excluding

		diversified mutual funds of a publicly traded company-Johnson & Johnson Advisor-Janssen Pharmaceuticals (J&J) Stocks or stock options, excluding diversified mutual funds-Pfizer, Inc. (Relationship has ended) Grant or research support-Genentech Consulting Fee-Neuvogen (Relationship has ended) Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended) Consulting Fee-Daiichi Sankyo (Relationship has ended) Honoraria-Thermo Fisher (Relationship has ended) - 05/26/2025
Katherine L Nathanson, MD	Other Planning Committee Member	Nothing to disclose - 01/04/2025
Jennifer Morrisette, PhD	Other Planning Committee Member	Advisor-AbbVie, Inc. (Relationship has ended) Stocks or stock options, excluding diversified mutual funds of a publicly traded company-ThermoFisher - 10/17/2024
Roger B Cohen, MD	Other Planning Committee Member	Consulting Fee-Actuate Consulting Fee-Tasca Consulting Fee-Ono - 05/24/2025
Megan Roy	Nurse Planner	Speakers Bureau-Astra Zeneca Pharmaceuticals - 05/19/2025
Simon B Chen, MD	Co-Director	Nothing to disclose - 11/26/2024
Michael Christensen, MD	Faculty	Nothing to disclose - 06/09/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected